You are here: Home: Audio Program Guide: LCU Nurses 1 | 2007 Audio: LCU Nurses 1 | 2007

 
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Sandler, MD Alan B Sandler, MD
Associate Professor of Medicine
Medical Director, Thoracic Oncology
Director, Vanderbilt-Ingram Cancer
Center Affiliate Network Program
Vanderbilt University Medical Center
Division of Hematology/Oncology
Nashville, Tennessee
  
  Click here to download entire interview  
Track 1 Clinical factors affecting the use of adjuvant chemotherapy in the treatment of non-small cell lung cancer (NSCLC)
Track 2 Comorbidities and performance status to determine tolerability of adjuvant chemotherapy
Track 3 Cure rates for patients with resected NSCLC and the impact of adjuvant chemotherapy
Track 4 Chemotherapy selection in the adjuvant setting
Track 5 Potential side effects associated with adjuvant chemotherapy
Track 6 Clinical trials evaluating nanoparticle albumin-bound (nab) paclitaxel in NSCLC
Track 7 ECOG-E1505: Adjuvant trial of bevacizumab in combination with cisplatin-based chemotherapy
Track 8 Mechanisms of action of bevacizumab
Track 9 Side effects and toxicities associated with bevacizumab
Track 10 Erlotinib: Mechanisms of action and identification of patients who may benefit
Track 11 Side effects associated with erlotinib
Track 12 Perspectives of patients with NSCLC on adjuvant therapy
Track 13 Clinical use of bevacizumab and erlotinib in the treatment of lung cancer
Track 14 Second-line therapy for patients with Stage IV NSCLC: Role of erlotinib

 
Culkin, MD Ann Culkin, RN, OCN
Thoracic Oncology Service
Ambulatory Nursing
Memorial Sloan-Kettering
Cancer Center
New York, New York
  
  Click here to download entire interview  
Track 1 Psychosocial considerations in patients receiving adjuvant therapy
Track 2 Comorbidities and chemotherapy selection in the adjuvant setting
Track 3 Prevention and treatment of constipation
Track 4 Counseling patients on symptoms to report when receiving chemotherapy
Track 5 Management of treatment-related fatigue and weight loss
Track 6 Educating patients on side effects associated with docetaxel
Track 7 Erlotinib in the metastatic setting
Track 8 Counseling patients about erlotinib-related skin rash
 
Eaby, MD Beth Eaby, MSN, CRNP, OCN
Outpatient Thoracic Oncology
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
  
  Click here to download entire interview  
Track 1 Psychosocial considerations related to smoking and lung cancer
Track 2 Counseling patients with locally advanced disease about chemoradiation therapy
Track 3 Selection of first-line therapy for patients with metastatic disease
Track 4 Counseling patients with metastatic disease about the risks and benefits of bevacizumab
Track 5 Impact of bevacizumab on hypertension and wound healing
Track 6 Dose escalation with erlotinib and resulting response and rash
Track 7 Management of rash secondary to erlotinib
Track 8 Correlation between treatment response and development of rash in patients on erlotinib
Track 9 Grading system for rashes to assist clinicians with treatment decisions
Track 10 Patient acceptance of erlotinib-induced rash in the adjuvant setting

 
Tyson, MD Leslie Tyson, MS, APRN-BC, OCN
Nurse Practitioner
Thoracic Oncology Service
Memorial Sloan-Kettering
Cancer Center
New York, New York
  
  Click here to download entire interview  
Track 1 Clinical trial of preoperative chemotherapy in combination with bevacizumab
Track 2 Rationale for evaluating cisplatin, docetaxel and bevacizumab in a clinical trial setting
Track 3 Patients’ willingness to participate in clinical trials
Track 4 Clinical response to bevacizumab monotherapy
Track 5 Quality of life on bevacizumab combined with chemotherapy
Track 6 Complete pathologic response to neoadjuvant chemotherapy in combination with bevacizumab
Track 7 Potential benefits of nab paclitaxel
Track 8 EGFR mutations and response to tyrosine kinase inhibitors
Track 9 Clinical trial of neoadjuvant gefitinib
Track 10 Quality of life on gefitinib

Griffin, MD Jeanne Griffin, NP
Nurse Practitioner
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
  
  Click here to download entire interview  
Track 1 Side effects and quality of life with cisplatin/docetaxel versus carboplatin/paclitaxel
Track 2 Utilization of nab paclitaxel in the treatment of lung cancer
Track 3 Pilot study of adjuvant carboplatin, paclitaxel and bevacizumab
Track 4 Sequence of therapy for patients with EGFR mutations
Track 5 Management of side effects secondary to erlotinib
Track 6 Erlotinib in nonsmokers and those with EGFR mutations